Monoclonal antibodies for treating gastric cancer: promises and pitfalls

Area of Science:

• Oncology
• Gastroenterology
• Pharmacology

Background:

• Gastric cancer (GC) has a poor prognosis, especially in advanced stages, with limited chemotherapy efficacy.
• Biotherapies targeting novel pathways are an emerging strategy for GC treatment.
• Current approved monoclonal antibodies (trastuzumab, ramucirumab) are often used with cytotoxics, with other agents showing mixed results.

Purpose of the Study:

• To review the achievements and limitations of monoclonal antibodies in gastric cancer treatment.
• To propose strategies for overcoming failures in biotherapy development for GC.
• To discuss optimizing the use of trastuzumab and ramucirumab in advanced GC.

Main Methods:

• Literature review of clinical trials and studies on monoclonal antibodies in gastric cancer.
• Analysis of factors contributing to the failure of biotherapy development.
• Evaluation of potential improvements for trastuzumab and ramucirumab efficacy.

Main Results:

• Trastuzumab efficacy may be enhanced by combination therapies or continuation in second-line treatment.
• Ramucirumab requires further investigation for first-line use, optimal dosing, and predictive biomarkers.
• Failures in biotherapy development may stem from study design, PK/PD knowledge gaps, and inter-patient variability.

Conclusions:

• Optimizing monoclonal antibody therapy, including dosing and combinations, is crucial for improving outcomes in advanced gastric cancer.
• Further research into predictive biomarkers and personalized dosing is essential for ramucirumab and other biotherapeutics.
• Addressing inter-patient variability and study design limitations can enhance the development of effective biotherapies for GC.